Adicet Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACET research report →
About the company
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies.
- CEO
- Chen Schor
- IPO
- 2018
- Employees
- 152
- HQ
- Boston, MA, US
Price Chart
- Market Cap
- $84.13M
- P/E
- -0.89
- P/S
- 0.00
- P/B
- 0.69
- EV/EBITDA
- -0.60
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -80.35%
- ROIC
- -73.91%
- Revenue
- $0 · 0.00%
- Net Income
- $-116,803,000 · 0.27%
- EPS
- $-16.95 · 20.35%
- Op Income
- $-122,114,000
- FCF YoY
- -3.73%
- 52W High
- $17.44
- 52W Low
- $6.01
- 50D MA
- $8.09
- 200D MA
- $9.07
- Beta
- 1.59
- Avg Volume
- 115.20K
Get TickerSpark's AI analysis on ACET
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 19, 26 | Schor Chen | other | 55,000 |
| Jun 19, 26 | Aftab Blake | other | 55,000 |
| Jun 21, 26 | DUBIN STEVE | other | 4,200 |
| Jun 21, 26 | Chodakewitz Jeffrey | other | 4,200 |
| Jun 21, 26 | Grissinger Michael | other | 4,200 |
| Jun 21, 26 | Sinclair Andrew | other | 4,200 |
| Jun 21, 26 | Peng Katie | other | 4,200 |
| Jun 21, 26 | Klickstein Lloyd | other | 4,200 |
| Apr 27, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 250,000 |
| Apr 27, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 250,000 |
Our ACET coverage
Recent articles, reports, and earnings notes.
Want a deeper read on ACET?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.